# A Parent’s Guide to Cannabis and Teen Anxiety: What the Research Supports, What It Warns About, and What Actually Treats Adolescent Anxiety > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-and-teen-anxiety-what-the-evidence-shows/ > **Published:** 2026-09-04T22:52:09-04:00 | **Last Modified / Clinically Audited:** 2026-10-14T08:55:37-04:00 > **Clinical Summary:** Cannabis and teen anxiety: no trial supports cannabis for adolescent anxiety, the developmental risk data are substantial, and effective treatments exist. --- CED Clinical Relevance #58High Safety RelevanceParents ask this question because a teenager has told them cannabis is the only thing that calms them down. The honest answer requires separating what is true about that experience from what the evidence supports doing about it, and the developmental risk data make the stakes concrete. A worried parent searching for whether cannabis helps a teenager’s anxiety deserves a direct answer rather than a balanced-sounding one. No randomized trial supports cannabis as a treatment for adolescent anxiety. The treatments that do have trial evidence work well, and the developmental risk literature attached to adolescent cannabis use is substantial enough to state plainly. Clinical Insight | CED Clinic The largest randomized trial of adolescent anxiety treatment, published in the *New England Journal of Medicine*, found that 80.7 percent of children improved on combined cognitive behavioral therapy and sertraline, compared with 23.7 percent on placebo. Effective treatment for this condition exists and is well characterized. The closest thing to cannabinoid evidence in young people with anxiety is a 31-participant open-label trial of pharmaceutical cannabidiol in treatment-resistant cases, with no control group and adverse events in 80.6 percent of participants. That is a signal worth studying, not a basis for a parent to act on. Adolescent HealthAnxietyCannabis RiskEvidence-Based TreatmentClinical Research AudienceParents, caregivers, and clinicians working with adolescentsPrimary TopicCannabis, adolescent anxiety, and the evidence-based alternativesSource[Read the full source](https://doi.org/10.1001/jamapsychiatry.2018.4500) Why This Matters Anxiety disorders are among the most common psychiatric conditions in adolescence, and a teenager who has found something that reduces the feeling in the moment will reasonably conclude it is working. Distinguishing acute relief from treatment is the central task here, and it is not a semantic distinction. This is a page about what a parent should do next, and the answer is the same regardless of how the conversation started: an evaluation by a clinician who treats adolescent anxiety, not a product decision. Start With What Does Work, Because It Works Well The Child/Adolescent Anxiety Multimodal Study remains the reference trial. Published in the *New England Journal of Medicine* by John Walkup and colleagues, it randomized 488 children aged 7 to 17 with a primary diagnosis of separation anxiety disorder, generalized anxiety disorder, or social phobia to 14 sessions of cognitive behavioral therapy, sertraline at up to 200 mg per day, the combination, or placebo for 12 weeks. The proportion rated very much or much improved was 80.7 percent for the combination, 59.7 percent for cognitive behavioral therapy alone, and 54.9 percent for sertraline alone, against 23.7 percent for placebo. All three active treatments beat placebo, and the combination beat both monotherapies. Adverse events including suicidal and homicidal ideation were no more frequent with sertraline than with placebo, and no child in the trial attempted suicide. Those numbers are the reason this page opens here rather than with cannabis. A parent weighing options is not choosing between an unproven option and nothing. They are choosing between an unproven option and a treatment with a four-in-five response rate in the best available trial. What Cannabinoid Research in Young People Actually Consists Of There is one study worth taking seriously, and its limitations are as important as its result. Maximus Berger and colleagues at Orygen in Melbourne enrolled 31 young people aged 12 to 25 with a diagnosed anxiety disorder who had not improved despite cognitive behavioral therapy, antidepressant medication, or both. All participants received add-on pharmaceutical cannabidiol on a fixed-flexible schedule titrated up to 800 mg per day for 12 weeks. Mean scores on the Overall Anxiety Severity and Impairment Scale fell from 10.8 to 6.3, a 42.6 percent reduction. Depressive symptoms, clinician-rated severity, and functioning improved as well. Adverse events were reported in 25 of 31 participants, or 80.6 percent, including fatigue, low mood, and hot flushes or chills. There were no serious or unexpected adverse events. This was an open-label trial with no control group. Everyone knew they were receiving cannabidiol, everyone was already engaged in specialist care, and anxiety scales improve substantially under those conditions even without an active drug. The authors said so themselves, concluding that randomized controlled trials are needed to confirm efficacy and longer-term safety. That conclusion is the honest one, and it is not a green light. It is also worth noting what this trial was not. It was not cannabis. It was a pharmaceutical-grade cannabidiol preparation, dosed and monitored inside a youth mental health research service, in patients who had already failed standard treatment. None of those conditions describe a teenager buying a product. The Negative Cannabidiol Evidence Belongs Here Too Selective reporting is the main way this topic goes wrong, so the failures deserve equal space. A double-blind, randomized, placebo-controlled trial published in *Psychopharmacology* tested single oral doses of cannabidiol at 150 mg, 300 mg, or 600 mg against placebo in 61 healthy young adults, using a well-established carbon dioxide inhalation challenge that reliably provokes fear and panic symptoms. There was no effect of condition on self-reported fear, on panic symptoms, or on heart rate. The authors described it as the first study to document that cannabidiol does not reduce fear reactivity in humans. One negative challenge study does not settle whether cannabidiol helps clinical anxiety, and provoked fear in healthy volunteers is not the same construct as an anxiety disorder. It does complicate the simple story in which cannabidiol is a reliable anxiolytic, and it is the kind of result that rarely appears in consumer-facing articles about CBD and anxiety. The Developmental Risk Data, Reported Accurately A systematic review and meta-analysis in *JAMA Psychiatry* by Gabriella Gobbi and colleagues pooled 11 longitudinal studies comprising 23,317 individuals, examining cannabis use before age 18 and outcomes in young adulthood between ages 18 and 32, with estimates adjusted for baseline symptoms. The odds ratio for developing depression was 1.37. The odds ratio for suicidal ideation was 1.50, and for suicide attempt it was 3.46. The pooled odds ratio for anxiety was 1.18 and was not statistically significant, with a confidence interval from 0.84 to 1.67. That last result should be reported as it stands: this meta-analysis did not find a significant link between adolescent cannabis use and later anxiety, even though it did find one for depression and suicidality. The psychosis literature is separate and stronger. A meta-analysis in *Schizophrenia Bulletin* covering 66,816 individuals found an odds ratio of 3.90 for schizophrenia and related outcomes among the heaviest cannabis users compared with non-users, with a consistent dose-response relationship. A multicentre case-control study across 11 sites published in *The Lancet Psychiatry* found daily cannabis use associated with a 3.2-fold odds of psychotic disorder, rising to 4.8-fold for daily use of high-potency products. The authors of the depression meta-analysis framed the individual-level risk as moderate to low while emphasizing that the number of adolescents using cannabis makes the population burden significant. Both halves of that sentence are worth carrying. Why Relief in the Moment and Harm Over Time Can Both Be Real A teenager who says cannabis is the only thing that calms them down is usually describing something accurate. Acute anxiolysis at some doses is a genuine pharmacologic effect, and dismissing the report damages the conversation without changing the behavior. What complicates it is that regular use creates its own anxiety. A meta-analysis in *JAMA Network Open* covering 47 studies and 23,518 participants estimated pooled cannabis withdrawal syndrome prevalence at 47 percent among people with regular or dependent use, with daily use associated with higher prevalence. Irritability, restlessness, sleep disruption, and anxiety are core features, and they resolve with the next use. That loop is indistinguishable from treatment while it is happening. Relief arrives, the relief is real, and the interval before the next dose becomes progressively less comfortable. A teenager experiencing that pattern will report with complete honesty that cannabis is treating their anxiety, and the pattern will still be getting worse. This is why the clinical answer is not to argue about whether it helps. It is to get an accurate picture of how much, how often, and for how long, alongside a proper anxiety evaluation. What a Parent Should Actually Do Book an evaluation with a clinician who treats adolescent anxiety, usually starting with the pediatrician or family physician and moving to child and adolescent psychiatry or psychology. Anxiety disorders in this age group are diagnosable and treatable, and the delay between recognizing the problem and starting treatment is the variable most within a family’s control. Bring the cannabis information to that visit rather than treating it as a separate disciplinary matter. Frequency, route, product type, and how long it has been going on all change the clinical picture, and a teenager is more likely to be accurate if the framing is medical rather than punitive. Do not source cannabis or cannabidiol products for a minor on the strength of the research above. The one supportive study used a pharmaceutical preparation, in a specialist research service, in patients who had already failed standard treatment, with no control group. Retail products differ in content and purity, cannabidiol has documented interactions with medications including some antiepileptics, and no product sold to consumers has been tested for adolescent anxiety. If a clinician does consider a cannabinoid in a specific case, that decision belongs to a specialist who is managing the whole picture and can monitor for interactions and adverse effects. The route to that conversation runs through an evaluation, not around one. Study SnapshotAnchor ReviewAssociation of Cannabis Use in Adolescence and Risk of Depression, Anxiety, and Suicidality in Young Adulthood: A Systematic Review and Meta-analysisDesignSystematic review and random-effects meta-analysis of longitudinal and prospective studies; databases searched from inception to January 2017Included Studies11 studies comprising 23,317 individuals, from 3,142 screened articlesExposureCannabis use assessed before age 18; outcomes ascertained between ages 18 and 32DepressionPooled odds ratio 1.37 (95% CI 1.16 to 1.62)AnxietyPooled odds ratio 1.18 (95% CI 0.84 to 1.67), not statistically significantSuicidalitySuicidal ideation odds ratio 1.50 (1.11 to 2.03); suicide attempt 3.46 (1.53 to 7.84)JournalJAMA Psychiatry 2019;76(4):426-434PMID / DOI30758486 / 10.1001/jamapsychiatry.2018.4500Treatment BenchmarkWalkup et al., New England Journal of Medicine 2008;359(26):2753-2766; 488 children aged 7 to 17; improvement 80.7% combination, 59.7% CBT, 54.9% sertraline, 23.7% placebo (PMID 18974308)Cannabidiol in YouthBerger et al., Journal of Clinical Psychiatry 2022;83(5):21m14130; open-label, 31 participants aged 12 to 25 with treatment-resistant anxiety; OASIS scores fell 42.6%; adverse events in 80.6% (PMID 35921510) How Strong Is This Evidence? The treatment evidence for adolescent anxiety is strong. A 488-participant randomized controlled trial with a placebo arm and clear separation between conditions is about as good as psychiatric treatment evidence gets in this age group. The cannabinoid evidence in young people with anxiety is weak by design rather than by accident. One open-label trial with 31 participants and no control group cannot distinguish drug effect from expectation, regression to the mean, or the effect of being in a specialist service for 12 weeks. Where This Paper Deserves Skepticism Longitudinal studies of adolescent cannabis use cannot fully separate cannabis from what precedes it. Teenagers who use cannabis differ from those who do not in family history, adverse experiences, and existing symptoms, and adjustment for baseline symptoms reduces that problem without eliminating it. The anxiety result in the depression meta-analysis was null and should be treated that way. Reporting the significant depression and suicidality findings while implying the anxiety finding went the same direction would be exactly the selective reading this page is arguing against. What This Paper Does Not Show None of this shows that cannabis causes anxiety disorders in adolescents, and the largest relevant meta-analysis specifically did not find a significant association with later anxiety. What it shows is elevated odds of depression and suicidality, and a separate and stronger dose-dependent association with psychotic outcomes. The cannabidiol research also does not show that pharmaceutical cannabidiol is ineffective in youth anxiety. An uncontrolled trial with a large apparent improvement is a reason to run a randomized trial, and that trial has not been reported. How This Fits With the Broader Clinical Conversation Adolescent anxiety and adolescent cannabis use overlap heavily in the same population, at the same developmental stage, during a period when brain systems that cannabinoids act on are still maturing. Untangling which came first is one of the hardest problems in developmental psychiatry and will not be solved by better cross-sectional data. The more actionable point is that the treatment side of this question is not in doubt. Whatever the causal story turns out to be, adolescent anxiety disorders respond to treatments that have been tested against placebo in children, and access to those treatments is the rate-limiting step for most families. Dr. Caplan’s Take I take the teenager’s report seriously. When a sixteen-year-old tells me cannabis is the only thing that stops the feeling, they are not lying and they are usually not exaggerating. Arguing with that observation is the fastest way to end the conversation. What I try to get across is that the relief is real and the arrangement is unstable. Something that works within minutes and wears off within hours will, over months, reorganize a young person’s day around the interval between doses. That is not a moral claim. It is how short-acting relief behaves in a developing nervous system. And I will say the thing I say to every parent who asks: I do not recommend cannabis for an adolescent with anxiety, and the evidence gives me no reason to. The treatments that work for this condition have been tested against placebo in children and they perform well. That is where the effort should go. Clinical Bottom Line No randomized trial supports cannabis as a treatment for adolescent anxiety. The one supportive cannabinoid study in young people used pharmaceutical cannabidiol, in a specialist research service, without a control group, in patients who had already failed standard treatment. Meanwhile, cognitive behavioral therapy and sertraline produced response rates of 59.7 and 54.9 percent against 23.7 percent for placebo in a 488-child randomized trial, and 80.7 percent in combination. A worried parent’s next step is an evaluation, not a product. What a Careful Reader Should Take Away Notice that the anxiety finding in the adolescent risk meta-analysis was null while the depression, suicidal ideation, and suicide attempt findings were not. Any source that presents adolescent cannabis use as a proven cause of later anxiety is overstating that literature, and any source that uses the null anxiety result to imply adolescent cannabis use is benign is ignoring the rest of the same table. Evidence Interpretation Guide Table of Contents - [How to read evidence about a treatment for a minor](#How_to_read_evidence_about_a_treatment_for_a_minor) - [Cannabis and Adolescent Anxiety, Seen From Eight Angles](#Cannabis_and_Adolescent_Anxiety_Seen_From_Eight_Angles)[For the parent reading this at 2 a.m.](#For_the_parent_reading_this_at_2_am) - [Screen for both problems at once](#Screen_for_both_problems_at_once) - [The risk literature has real limits](#The_risk_literature_has_real_limits) - [What an open-label trial cannot tell you](#What_an_open-label_trial_cannot_tell_you) - [The self-medication question is old and unresolved](#The_self-medication_question_is_old_and_unresolved) - [What effective treatment looks like in practice](#What_effective_treatment_looks_like_in_practice) - [The trial that should be run](#The_trial_that_should_be_run) - [Minors are the population where caution costs least](#Minors_are_the_population_where_caution_costs_least) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) ## How to read evidence about a treatment for a minor The Research QuestionIs cannabis use during adolescence associated with depression, anxiety, or suicidality in young adulthood?The Patient QuestionMy teenager says cannabis is the only thing that helps their anxiety. Is that true, and what should I do?The Bottom LineAcute relief is real and is not treatment. Adolescent anxiety disorders respond to therapies tested against placebo in children. Cannabis has never been tested for this indication in this age group. CED Perspective Lens ## Cannabis and Adolescent Anxiety, Seen From Eight Angles The risk data, the treatment data, and the gap between them, read through the lenses that matter in practice. Lens OverviewNo randomized trial has tested cannabis for adolescent anxiety; the single open-label cannabidiol study in young people had 31 participants and no control arm, while established treatments for adolescent anxiety show response rates around 55 to 81 percent against 24 percent for placebo. #### For the parent reading this at 2 a.m. Your teenager is probably describing something real when they say cannabis calms them. That does not make it a treatment, and believing them is compatible with not agreeing to it. The useful next step is small and concrete: an appointment with someone who treats adolescent anxiety, with the cannabis information brought into that room rather than kept out of it. Lens takeawayBelieve the report, book the evaluation, and bring the cannabis details to the clinician. #### Screen for both problems at once An adolescent presenting with anxiety and regular cannabis use has two clinical problems that interact, and treating either in isolation tends to fail. Withdrawal-driven anxiety in the interval between doses is easy to mistake for the primary disorder. Frequency, route, product potency, and duration of use change the assessment. A binary yes or no on the intake form discards the information that matters. Lens takeawayQuantify use, then treat the anxiety disorder with something that has been tested in children. #### The risk literature has real limits Longitudinal cohorts cannot randomize adolescents to cannabis, so residual confounding by family history, trauma exposure, and prodromal symptoms is unavoidable. Adjusting for baseline symptoms helps and does not solve it. The anxiety-specific finding in the largest relevant meta-analysis was not statistically significant, and stating otherwise would misrepresent it. Lens takeawayThe depression and suicidality signals are the robust ones. The anxiety signal is not. #### What an open-label trial cannot tell you A 42.6 percent reduction in anxiety scores sounds decisive until you note that everyone knew what they were taking, there was no placebo arm, and participants were receiving specialist care throughout the 12 weeks. In the placebo-controlled adolescent anxiety trial, the placebo response rate was 23.7 percent. Uncontrolled improvement of that size is routine in this population. Lens takeawayCite the cannabidiol youth study as a rationale for a randomized trial, never as evidence of benefit. #### The self-medication question is old and unresolved Clinicians have observed the association between anxiety and substance use for decades, and the direction of causation has been argued the whole time. Longitudinal data have narrowed the question without closing it. What has changed is potency. Case-control data across 11 European sites found daily use of high-potency cannabis associated with nearly five-fold odds of psychotic disorder, compared with 3.2-fold for daily use generally. Lens takeawayThe exposure adolescents encounter today is not the exposure most older studies measured. #### What effective treatment looks like in practice In the reference trial, cognitive behavioral therapy meant 14 structured sessions, and sertraline was titrated up to 200 mg per day over 12 weeks. Both take weeks, which is the honest disadvantage compared with something that works in minutes. Setting that expectation in advance is part of the work. A family that expects improvement in three days will abandon an effective treatment in week two. Lens takeawayName the timeline up front so a slow-acting effective treatment gets a fair trial. #### The trial that should be run A randomized, placebo-controlled trial of pharmaceutical cannabidiol as an add-on in adolescents with treatment-resistant anxiety would answer the question the open-label study raised. The authors of that study called for exactly this. Until it exists, the gap between a promising uncontrolled result and a clinical recommendation stays wide, and filling it with consumer products is not a substitute. Lens takeawayA randomized add-on trial in treatment-resistant adolescent anxiety is the missing study. #### Minors are the population where caution costs least The developmental risk literature covering depression, suicidality, and psychosis is substantial enough that adolescent cannabis exposure warrants prevention effort on its own terms, separate from any question about anxiety. Access restrictions for minors are among the least controversial features of cannabis policy, and the evidence above is the reason they exist. Lens takeawayNothing in this evidence base argues for loosening adolescent access. Massachusetts Clinical Care & Certification Are you a Massachusetts resident seeking physician-supervised cannabinoid therapy? Learn more about scheduling a telehealth consultation with a certified [Massachusetts medical marijuana doctor](https://cedclinic.com/massachusetts-medical-marijuana-doctor/), or read our step-by-step 2026 guide on [how to get a medical marijuana card in Massachusetts](https://cedclinic.com/how-to-get-a-medical-marijuana-card-in-massachusetts/) to save ~20% on state dispensary taxes. Related Reading at CED ClinicContinue exploring the evidence[Cannabis and Anxiety: Finding Relief Without the Panic](https://cedclinic.com/cannabis-and-anxiety-finding-relief-without-the-panic/) The adult picture, where the dose-dependence of anxiety effects is clearest. [Read the adult evidence](https://cedclinic.com/cannabis-and-anxiety-finding-relief-without-the-panic/)[California Study Tracks Adolescent CUD After Cannabis Legalization](https://cedclinic.com/california-adolescent-cud-legalization-2026/) Population data on how adolescent cannabis use disorder has moved in a legal market. [See the state data](https://cedclinic.com/california-adolescent-cud-legalization-2026/)[Cannabis Use Disorder Risk, Internet Use, and Depression](https://cedclinic.com/cannabis-use-disorder-internet-use-depression/) A longitudinal look at how cannabis use disorder risk clusters with mood symptoms in young people. [Read the Quebec study](https://cedclinic.com/cannabis-use-disorder-internet-use-depression/) Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) ## Frequently Asked Questions Does cannabis help teenage anxiety? No trial has tested cannabis for adolescent anxiety, so there is no evidence that it does. The closest research is a 31-participant open-label study of pharmaceutical cannabidiol in people aged 12 to 25 with treatment-resistant anxiety, which had no control group. Teenagers frequently report genuine relief in the moment, but acute relief is a different thing from treatment, and no product sold to consumers has been tested for this purpose. What actually treats anxiety in teenagers? Cognitive behavioral therapy and selective serotonin reuptake inhibitors, alone or together. In a 488-child randomized trial published in the New England Journal of Medicine, 80.7 percent improved on combined cognitive behavioral therapy and sertraline, 59.7 percent on therapy alone, and 54.9 percent on sertraline alone, compared with 23.7 percent on placebo. Both treatments take weeks rather than minutes, which is worth expecting in advance. Does adolescent cannabis use cause anxiety later in life? The largest meta-analysis on this question did not find a significant association. Pooling 11 longitudinal studies and 23,317 individuals, the odds ratio for anxiety in young adulthood after adolescent cannabis use was 1.18 with a confidence interval crossing 1. The same analysis did find significant associations with depression, suicidal ideation, and suicide attempt, so the null anxiety result should not be read as reassurance overall. Is CBD safe for a teenager with anxiety? Safety has not been established for that use. The one trial in young people used a pharmaceutical preparation titrated to 800 mg per day under specialist supervision and reported adverse events in 80.6 percent of participants, including fatigue and low mood. Cannabidiol also interacts with several medications. Retail products vary in content and purity, and none has been tested in adolescents with anxiety disorders. Why does my teenager say cannabis is the only thing that works? Because the acute effect is real and arrives quickly, and because regular use creates its own anxiety between doses. A meta-analysis of 47 studies found that roughly 47 percent of people with regular or dependent cannabis use experience a withdrawal syndrome, in which irritability, restlessness, and anxiety build until the next use. That cycle feels exactly like a treatment that is working. What are the risks of cannabis use during adolescence? The best-supported signals are psychiatric. A meta-analysis of 66,816 individuals found the heaviest cannabis users had roughly four-fold odds of schizophrenia and related outcomes, with a dose-response pattern. A multicentre European study found daily use associated with 3.2-fold odds of psychotic disorder and daily high-potency use with 4.8-fold odds. Adolescent use is also associated with later depression and suicidality. Should I let my teenager try CBD gummies for anxiety? That is not a decision to make on the strength of current evidence. Consumer cannabidiol products have not been tested in adolescents with anxiety disorders, content and purity vary between products, and cannabidiol has documented drug interactions. If a cannabinoid is ever appropriate in a specific case, that judgment belongs to a specialist managing the whole clinical picture, and it follows an evaluation rather than replacing one. How do I bring up cannabis with my teenager without shutting down the conversation? Frame it as a medical question rather than a disciplinary one. Ask how often, what form, and how long it has been going on, and say plainly that you believe them when they say it helps in the moment. Then bring that information to the clinician doing the anxiety evaluation. Accurate use history changes the assessment, and a punitive framing reliably produces an inaccurate one. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).